Patrick Treanor
Directeur/Bestuurslid bij KALVISTA PHARMACEUTICALS, INC.
Vermogen: - $ op 30-04-2024
Profiel
Patrick A.
Treanor is an Independent Director at KalVista Pharmaceuticals, Inc., a Director at XORTX Therapeutics, Inc., and the former President of Vifor Pharma, Inc. He was also the Chief Operating Officer at Pathalys Pharma, Inc. and held Vice President positions at Oscient Pharmaceuticals Corp., Insulet Corp., AMAG Pharmaceuticals, Inc., and Relypsa, Inc. Treanor holds a Master's in Business Administration from Rensselaer Polytechnic Institute and an undergraduate degree from Bryant University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
26-09-2023 | 0 ( -.--% ) | - $ | 30-04-2024 |
Actieve functies van Patrick Treanor
Bedrijven | Functie | Begin |
---|---|---|
KALVISTA PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 26-05-2022 |
XORTX THERAPEUTICS INC. | Directeur/Bestuurslid | 31-12-2023 |
Pathalys Pharma, Inc.
Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | Operationeel Directeur | 01-07-2021 |
Eerdere bekende functies van Patrick Treanor
Bedrijven | Functie | Einde |
---|---|---|
Vifor Pharma, Inc.
Vifor Pharma, Inc. Medical/Nursing ServicesHealth Services Vifor Pharma, Inc. is an American company that specializes in iron deficiency, nephrology, and cardio-renal therapies. The company is based in Redwood. | President | 01-06-2021 |
INSULET CORPORATION | Verkoop & Marketing | 01-04-2015 |
Oscient Pharmaceuticals Corp.
Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01-01-2007 |
AMAG PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
RELYPSA INC | Corporate Officer/Principal | - |
Opleiding van Patrick Treanor
Rensselaer Polytechnic Institute | Masters Business Admin |
Bryant University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
KALVISTA PHARMACEUTICALS, INC. | Health Technology |
INSULET CORPORATION | Health Technology |
XORTX THERAPEUTICS INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Pathalys Pharma, Inc.
Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | Health Technology |
Relypsa, Inc.
Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Vifor Pharma, Inc.
Vifor Pharma, Inc. Medical/Nursing ServicesHealth Services Vifor Pharma, Inc. is an American company that specializes in iron deficiency, nephrology, and cardio-renal therapies. The company is based in Redwood. | Health Services |
AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
Oscient Pharmaceuticals Corp.
Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Commercial Services |